All In Biotech

Drug Trial Radar · NCT06679101

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Dec 16, 2024

Primary completion

Apr 28, 2031

Study completion Apr 28, 2031

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

Conditions

  • Multiple Myeloma
  • Newly Diagnosed Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Belantamab mafodotin will be administered.

  • LenalidomideDrug

    Lenalidomide will be administered.

  • DexamethasoneDrug

    Dexamethasone will be administered.

  • DaratumumabDrug

    Daratumumab will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: Up to approximately 7 years
  2. Number of Participants Achieving MRD Negative StatusTime frame: Up to approximately 7 years

Locations

181 sites in 24 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Mobile, Alabama · Recruiting

  • GSK Investigational Site

    Phoenix, Arizona · Recruiting

  • GSK Investigational Site

    Beverly Hills, California · Recruiting

  • GSK Investigational Site

    Pasadena, California · Recruiting

  • GSK Investigational Site

    Aurora, Colorado · Recruiting

  • GSK Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • GSK Investigational Site

    Englewood, Florida · Recruiting

  • GSK Investigational Site

    Lady Lake, Florida · Recruiting

  • GSK Investigational Site

    Pembroke Pines, Florida · Recruiting

  • GSK Investigational Site

    Saint Augustine, Florida · Recruiting

  • GSK Investigational Site

    Atlanta, Georgia · Recruiting

  • GSK Investigational Site

    Portland, Maine · Recruiting

  • GSK Investigational Site

    Worcester, Massachusetts · Recruiting

  • GSK Investigational Site

    Ann Arbor, Michigan · Recruiting

  • GSK Investigational Site

    Detroit, Michigan · Recruiting

  • GSK Investigational Site

    Billings, Montana · Recruiting

  • GSK Investigational Site

    Hackensack, New Jersey · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Stony Brook, New York · Recruiting

  • GSK Investigational Site

    Charlotte, North Carolina · Recruiting

  • GSK Investigational Site

    Winston-Salem, North Carolina · Recruiting

  • GSK Investigational Site

    Columbus, Ohio · Recruiting

  • GSK Investigational Site

    Providence, Rhode Island · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Kingwood, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Tyler, Texas · Recruiting

  • GSK Investigational Site

    Fairfax, Virginia · Recruiting

  • GSK Investigational Site

    Puyallup, Washington · Recruiting

  • GSK Investigational Site

    Capital Federal, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • GSK Investigational Site

    Córdoba, Argentina · Recruiting

  • GSK Investigational Site

    Rosario, Argentina · Recruiting

  • GSK Investigational Site

    Viedma, Argentina · Recruiting

  • GSK Investigational Site

    Fitzroy, Australia · Recruiting

  • GSK Investigational Site

    Herston, Australia · Recruiting

  • GSK Investigational Site

    St Leonards, Australia · Recruiting

  • GSK Investigational Site

    Gosford NSW, New South Wales, Australia · Recruiting

  • GSK Investigational Site

    Box Hill, Victoria, Australia · Recruiting

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.